BIOMAT Database Logo BIOMAT Database Logo

Discovery of Selective and Potent ATR Degrader for Exploration its Kinase-Independent Functions in Acute Myeloid Leukemia Cells. 2024

Yubo Wang, and Ruonan Wang, and Yanli Zhao, and Sheng Cao, and Chen Li, and Yanjie Wu, and Lan Ma, and Ying Liu, and Yuhong Yao, and Yue Jiao, and Yukun Chen, and Shuangwei Liu, and Kun Zhang, and Mingming Wei, and Cheng Yang, and Guang Yang
The State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University, Tianjin, 300071, P. R. China.

ATR has emerged as a promising target for anti-cancer drug development. Several potent ATR inhibitors are currently undergoing various stages of clinical trials, but none have yet received FDA approval due to unclear regulatory mechanisms. In this study, we discovered a potent and selective ATR degrader. Its kinase-independent regulatory functions in acute myeloid leukemia (AML) cells were elucidated using this proteolysis-targeting chimera (PROTAC) molecule as a probe. The ATR degrader, 8 i, exhibited significantly different cellular phenotypes compared to the ATR kinase inhibitor 1. Mechanistic studies revealed that ATR deletion led to breakdown in the nuclear envelope, causing genome instability and extensive DNA damage. This would increase the expression of p53 and triggered immediately p53-mediated apoptosis signaling pathway, which was earlier and more effective than ATR kinase inhibition. Based on these findings, the in vivo anti-proliferative effects of ATR degrader 8 i were assessed using xenograft models. The degrader significantly inhibited the growth of AML cells in vivo, unlike the ATR inhibitor. These results suggest that the marked anti-AML activity is regulated by the kinase-independent functions of the ATR protein. Consequently, developing potent and selective ATR degraders could be a promising strategy for treating AML.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D015470 Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES. Leukemia, Myelogenous, Acute,Leukemia, Nonlymphocytic, Acute,Myeloid Leukemia, Acute,Nonlymphocytic Leukemia, Acute,ANLL,Acute Myelogenous Leukemia,Acute Myeloid Leukemia,Acute Myeloid Leukemia with Maturation,Acute Myeloid Leukemia without Maturation,Leukemia, Acute Myelogenous,Leukemia, Acute Myeloid,Leukemia, Myeloblastic, Acute,Leukemia, Myelocytic, Acute,Leukemia, Myeloid, Acute, M1,Leukemia, Myeloid, Acute, M2,Leukemia, Nonlymphoblastic, Acute,Myeloblastic Leukemia, Acute,Myelocytic Leukemia, Acute,Myelogenous Leukemia, Acute,Myeloid Leukemia, Acute, M1,Myeloid Leukemia, Acute, M2,Nonlymphoblastic Leukemia, Acute,Acute Myeloblastic Leukemia,Acute Myeloblastic Leukemias,Acute Myelocytic Leukemia,Acute Myelocytic Leukemias,Acute Myelogenous Leukemias,Acute Myeloid Leukemias,Acute Nonlymphoblastic Leukemia,Acute Nonlymphoblastic Leukemias,Acute Nonlymphocytic Leukemia,Acute Nonlymphocytic Leukemias,Leukemia, Acute Myeloblastic,Leukemia, Acute Myelocytic,Leukemia, Acute Nonlymphoblastic,Leukemia, Acute Nonlymphocytic,Leukemias, Acute Myeloblastic,Leukemias, Acute Myelocytic,Leukemias, Acute Myelogenous,Leukemias, Acute Myeloid,Leukemias, Acute Nonlymphoblastic,Leukemias, Acute Nonlymphocytic,Myeloblastic Leukemias, Acute,Myelocytic Leukemias, Acute,Myelogenous Leukemias, Acute,Myeloid Leukemias, Acute,Nonlymphoblastic Leukemias, Acute,Nonlymphocytic Leukemias, Acute
D016159 Tumor Suppressor Protein p53 Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER. p53 Tumor Suppressor Protein,Cellular Tumor Antigen p53,Oncoprotein p53,TP53 Protein,TRP53 Protein,p53 Antigen,pp53 Phosphoprotein,Phosphoprotein, pp53
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D059748 Proteolysis Cleavage of proteins into smaller peptides or amino acids either by PROTEASES or non-enzymatically (e.g., Hydrolysis). It does not include Protein Processing, Post-Translational. Protein Degradation,Protein Digestion,Degradation, Protein,Degradations, Protein,Digestion, Protein,Digestions, Protein,Protein Degradations,Protein Digestions,Proteolyses
D064007 Ataxia Telangiectasia Mutated Proteins A group of PROTEIN SERINE-THREONINE KINASES which activate critical signaling cascades in double strand breaks, APOPTOSIS, and GENOTOXIC STRESS such as ionizing ultraviolet A light, thereby acting as a DNA damage sensor. These proteins play a role in a wide range of signaling mechanisms in cell cycle control. A-T Protein,AT Mutated Protein,ATM Protein,A T Protein,Mutated Protein, AT,Protein, A-T,Protein, AT Mutated

Related Publications

Yubo Wang, and Ruonan Wang, and Yanli Zhao, and Sheng Cao, and Chen Li, and Yanjie Wu, and Lan Ma, and Ying Liu, and Yuhong Yao, and Yue Jiao, and Yukun Chen, and Shuangwei Liu, and Kun Zhang, and Mingming Wei, and Cheng Yang, and Guang Yang
Discovery of a Potent and Selective Degrader for USP7.
August 2022, Angewandte Chemie (International ed. in English),
Yubo Wang, and Ruonan Wang, and Yanli Zhao, and Sheng Cao, and Chen Li, and Yanjie Wu, and Lan Ma, and Ying Liu, and Yuhong Yao, and Yue Jiao, and Yukun Chen, and Shuangwei Liu, and Kun Zhang, and Mingming Wei, and Cheng Yang, and Guang Yang
Discovery of Potent and Selective PI3Kδ Inhibitors for the Treatment of Acute Myeloid Leukemia.
April 2024, Journal of medicinal chemistry,
Yubo Wang, and Ruonan Wang, and Yanli Zhao, and Sheng Cao, and Chen Li, and Yanjie Wu, and Lan Ma, and Ying Liu, and Yuhong Yao, and Yue Jiao, and Yukun Chen, and Shuangwei Liu, and Kun Zhang, and Mingming Wei, and Cheng Yang, and Guang Yang
Discovery of indirubin-3'-aminooxy-acetamide derivatives as potent and selective FLT3/D835Y mutant kinase inhibitors for acute myeloid leukemia.
July 2022, European journal of medicinal chemistry,
Yubo Wang, and Ruonan Wang, and Yanli Zhao, and Sheng Cao, and Chen Li, and Yanjie Wu, and Lan Ma, and Ying Liu, and Yuhong Yao, and Yue Jiao, and Yukun Chen, and Shuangwei Liu, and Kun Zhang, and Mingming Wei, and Cheng Yang, and Guang Yang
Dual IKZF2 and CK1α degrader targets acute myeloid leukemia cells.
April 2023, Cancer cell,
Yubo Wang, and Ruonan Wang, and Yanli Zhao, and Sheng Cao, and Chen Li, and Yanjie Wu, and Lan Ma, and Ying Liu, and Yuhong Yao, and Yue Jiao, and Yukun Chen, and Shuangwei Liu, and Kun Zhang, and Mingming Wei, and Cheng Yang, and Guang Yang
Discovery of benzimidazole-indazole derivatives as potent FLT3-tyrosine kinase domain mutant kinase inhibitors for acute myeloid leukemia.
December 2023, European journal of medicinal chemistry,
Yubo Wang, and Ruonan Wang, and Yanli Zhao, and Sheng Cao, and Chen Li, and Yanjie Wu, and Lan Ma, and Ying Liu, and Yuhong Yao, and Yue Jiao, and Yukun Chen, and Shuangwei Liu, and Kun Zhang, and Mingming Wei, and Cheng Yang, and Guang Yang
Discovery of a Promising CBP/p300 Degrader XYD129 for the Treatment of Acute Myeloid Leukemia.
June 2024, Journal of medicinal chemistry,
Yubo Wang, and Ruonan Wang, and Yanli Zhao, and Sheng Cao, and Chen Li, and Yanjie Wu, and Lan Ma, and Ying Liu, and Yuhong Yao, and Yue Jiao, and Yukun Chen, and Shuangwei Liu, and Kun Zhang, and Mingming Wei, and Cheng Yang, and Guang Yang
Discovery of novel negletein derivatives as potent anticancer agents for acute myeloid leukemia.
April 2018, Chemical biology & drug design,
Yubo Wang, and Ruonan Wang, and Yanli Zhao, and Sheng Cao, and Chen Li, and Yanjie Wu, and Lan Ma, and Ying Liu, and Yuhong Yao, and Yue Jiao, and Yukun Chen, and Shuangwei Liu, and Kun Zhang, and Mingming Wei, and Cheng Yang, and Guang Yang
Discovery of the Potent and Selective ATR Inhibitor Camonsertib (RP-3500).
February 2024, Journal of medicinal chemistry,
Yubo Wang, and Ruonan Wang, and Yanli Zhao, and Sheng Cao, and Chen Li, and Yanjie Wu, and Lan Ma, and Ying Liu, and Yuhong Yao, and Yue Jiao, and Yukun Chen, and Shuangwei Liu, and Kun Zhang, and Mingming Wei, and Cheng Yang, and Guang Yang
A Kinase Inhibitor with Anti-Pim Kinase Activity is a Potent and Selective Cytotoxic Agent Toward Acute Myeloid Leukemia.
March 2019, Molecular cancer therapeutics,
Yubo Wang, and Ruonan Wang, and Yanli Zhao, and Sheng Cao, and Chen Li, and Yanjie Wu, and Lan Ma, and Ying Liu, and Yuhong Yao, and Yue Jiao, and Yukun Chen, and Shuangwei Liu, and Kun Zhang, and Mingming Wei, and Cheng Yang, and Guang Yang
Leukemia-derived dendritic cells in acute myeloid leukemia exhibit potent migratory capacity.
July 2005, Leukemia,
Copied contents to your clipboard!